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Acute kidney injury (AKI) following cardiac surgery is associated with increased morbidity 
and mortality, longer hospital stays, and significantly increased health care costs. The 
physiological functions performed by the kidney, which include acid-base control, blood 
pressure regulation, water balance, and waste excretion, are crucial to the maintenance of 
homeostasis and can only partially be accomplished using renal replacement therapy (RRT). 
A number of risk factors have been identified that should be recognized in order to counsel 
patients appropriately and attempt to prevent AKI. Several pharmacologic and therapeutic 
modalities have been suggested, with varying levels of evidence, to aid in prevention of AKI 
and limit the extent of injury and morbidity once renal dysfunction has been recognized. 
The purpose of this chapter is to review the epidemiology, prevention, diagnosis, and 
treatment of acute kidney injury following cardiac surgery. These topics will be reviewed in 
detail in the discussion that follows. 
2. Epidemiology 
The incidence of AKI following cardiac surgery has historically been difficult to determine. Mild 
renal injury (creatinine rise <25%) may occur in as many as 50% of patients undergoing cardiac 
surgery. Moderate kidney injury has been reported in 8-15% of patients, while up to 5% of 
patients develop renal failure requiring dialysis following cardiac surgery. (Shaw, Swaminathan 
et al. 2008) Individual reports differ significantly as a result of inconsistent definitions, varied 
surgeries, and a heterogeneous patient population.(Bellomo, Ronco et al. 2004)  
In many series, renal failure is defined as a 50% rise in serum creatinine, while others define 
it arbitrarily as a doubling of the creatinine, and yet others include only dialysis dependent 
patients in their analyses.(Bellomo, Kellum et al. 2004) The RIFLE and AKIN criteria were 
developed by panels of experts to provide a uniform definition of acute kidney injury and 
facilitate recommendations for patients suffering from renal failure.(Kellum, Mehta et al. 
2002; Mehta, Kellum et al. 2007) (Figure 1) These definitions rely upon serum creatinine 
levels and urine output to define and categorize the severity of kidney injury. Regardless of 
the definition, once renal failure progresses and a patient becomes dialysis dependant, 
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mortality rates rise considerably and are often reported to be above 50%.(Andersson, Ekroth 
et al. 1993; Chertow, Levy et al. 1998)  Even with the progress of modern medicine and 
implementation of newer dialysis technology, the mortality associated with postoperative 
renal failure has not noticeably improved. (Ympa, Sakr et al. 2005) One may suggest that this 
is because renal failure in itself is often not the primary problem, but only a sign of 
significant low cardiac output and multi-organ failure, however, this is likely not the case. 
Other authors have proposed that the high mortality associated with renal failure is not 
related to RRT itself, rather it predisposes patients to other morbidities. A large study 
reviewing 16,000 patients with contrast induced nephropathy suggested that patient’s 
whose hospitalisations were complicated by sepsis, coagulopathies, respiratory, or 
neurologic failure, were more likely to die during their hospitalisation, while it was rare for 
patients with uncomplicated renal failure not to survive. (Levy, Viscoli et al. 1996) Chertow et 
al, reporting on over 43,000 patients with AKI following cardiac surgery, found that these 
patients were more likely to suffer myocardial infarction, require reoperation for bleeding, and 
develop endocarditis or mediastinitis.(Chertow, Lazarus et al. 1997) Patients with renal failure 
also had an overall greater risk of death in the index hospitalization.  
 
Fig. 1. RIFLE and AKIN criteria. Reproduced from Reproduced with permission from 
Biomed Central (Cruz, Ricci et al. 2009) 
While patients with AKI requiring RRT demonstrate substantially elevated mortality rates, 
even patients with milder renal dysfunction not requiring RRT show decreased survival and 
worse outcomes compared to those without postoperative AKI.(1994; Conlon, Stafford-Smith 
et al. 1999) Although it may be intuitive that morbidity will increase with severe renal 
dysfunction, it is less obvious that a modest rise in creatinine can negatively affect quality of 
life and life expectancy.(Lassnigg, Schmidlin et al. 2004; Lassnigg, Schmid et al. 2008) In 
addition to increasing mortality, acute kidney injury prolongs ICU stay and increases the 
proportion of patients discharged to a nursing care facility. This data suggests that the ill-
effects of acute kidney injury are not simply a sign of sicker patients with other comorbid 
conditions, rather AKI is an independent predictor of morbidity and mortality following cardiac 
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surgery. As a result, all efforts must be made to identify patients at risk for AKI, focusing on 
prevention of renal dysfunction rather than simply treating it once the injury has occurred. 
3. Pathophysiology of AKI following cardiac surgery 
The pathophysiology and etiology of postoperative AKI in cardiac surgery is multifactorial, 
resulting from a combination vascular and tubular injury.(Mahon and Shorten 2006) A 
variety of events occur in the perioperative period that could individually and cumulatively 
result in renal dysfunction. During cardiopulmonary bypass (CPB), the kidneys are exposed 
to interruptions and alterations in blood flow due to changes in pump flow and the lack of 
pulsatility, which can lead to ischemia-reperfusion injury. Concurrently, the kidneys risk 
being affected by embolic materials originating from air entry into the circulation, platelet 
aggregates, lipids, and atheromatous plaques.(Sear 2005) Exposure to the CPB circuit 
initiates several cascades that can cause kidney injury, such as complement activation, free 
radical formation, and inflammatory cytokine production.(Mahon and Shorten 2006) 
Bellomo et al developed the following comprehensive list of pathophysiologic mechanisms 
behind AKI: (1) exogenous and endogenous toxins, (2) metabolic factors, (3) ischemia-
reperfusion, (4) neurohormonal activation, (5) inflammation, and (6) oxidative 
stress.(Bellomo, Auriemma et al. 2008) The sum of these factors culminates in a significant 
and constant risk of renal tubular injury in patients undergoing cardiac surgery. While it is 
important to appreciate the pathophysiology of renal dysfunction, understanding and 
considering the differential diagnosis is clearly necessary to provide appropriate therapy. 
Figure 2 summarizes the differential diagnosis of acute renal failure. 
 
Fig. 2. Classification and major causes of acute renal failure. NSAIDs = non-steroidal anti-
inflammatory agents; ACE = angiotensin-converting enzyme. Reproduced with permission 
from Elsevier (Lameire, Van Biesen et al. 2005) 
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4. Diagnosis of postoperative AKI 
Although new concepts such as RIFLE and AKIN have helped standardize the definition of 
AKI, the criteria involved in making the diagnosis can take hours to days, leading to 
delayed recognition of renal dysfunction. This delay may be partly responsible for the 
limited progress that has been made in preventing and treating postoperative renal failure, 
and highlights the need for more immediate markers of AKI. The present and future tools 
available to diagnose AKI in cardiac surgery will be discussed below.  
4.1 Creatinine 
When comparing the progress in the diagnosic tools available for AKI to that of 
myocardial infarction, the state-of-the-art is lagging significantly. Fifty years ago 
creatinine kinase (CK) was the only available marker for cardiac injury, as was serum 
creatinine for renal injury. In current practice, cardiac injury is identified through several 
laboratory tests, such as levels CK-MB, Troponin-I, Troponin-T, Myoglobin, and BNP. 
However, creatinine is still the only biomarker routinely used to identify kidney injury. 
Creatinine and urine output together are relied upon to assess global kidney function. 
While creatinine is a relatively specific marker of renal injury, its sensitivity can be called 
into question and it bears some inherent limitations. Circulating levels vary with age, 
gender, muscle mass, vigorous exercise, and medications. In addition, levels rise only 
when GFR is reduced by more than 50% and it can take up to 24 hours before there is a 
sufficient increase to allow for the diagnosis of AKI.(Bagshaw and Gibney 2008) In light of 
these shortcomings, there is a clear need for newer, more sensitive, methods of diagnosing 
renal dysfunction.  
4.2 Urine output 
The most readily available surrogate marker of renal function is urine output. Compared 
to creatinine, it is more sensitive to changes in renal hemodynamics. Unfortunately, 
variations in urine output are considerably less specific, except when severely diminished 
or absent. Oliguria is defined as urine output of less than 0.5mg/kg/hour. The presence 
of an oliguric state gives physicians a sign that their patient’s kidney function is at risk or 
already perturbed, however, the presence of normal urine output cannot provide 
assurance that renal function is unperturbed. In non-oliguric renal failure, the kidney’s 
ability to produce urine is preserved but its ability to excrete water-soluble waste 
products is lost or markedly reduced. The reality is that even the combination of urine 
output and serum creatinine cannot reliably diagnose renal injury in a timely manner. 
This once again highlights the importance of uncovering and validating other methods to 
identify AKI. 
4.3 Urinalysis 
In patients with decreased urine output or suspected acute kidney injury, urinalysis is an 
important tool that can differentiate prerenal from renal failure. Consequently, it can be very 
useful in guiding treatment. Table 1 describes select variables and their association with the 
etiology of acute kidney injury. 
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 Prerenal Renal 
Urinalysis Normal Abnormal 
Specific gravity 1.020 1.010 
Osmolality (mmol/kg) >500 >300 
Sodium (mmol/L) <20 >40 
Fractional excretion of sodium (%) <1 >2 
Fractional excretion of urea (%) <35 >35 
Fractional excretion of uric acid (%) <7 >35 
Fractional excretion of lithium <7 >15 
Low-molecular weight proteins Low High 
Brush border enzymes Low High 
Table 1. Important variables in differentiating prerenal from renal acute renal failure. 
Adapted from Lameire et al (Lameire, Van Biesen et al. 2005) 
4.4 Neutrophil gelatinase-associated lipocalin (NGAL)  
NGAL is a protein, known to bind small iron-carrying molecules, that is significantly 
upregulated in response to acute renal injury. Its concentration rises within three hours in 
response to renal tubular injury and can precede the rise in creatinine by more than 24 
hours.(Schmidt-Ott, Mori et al. 2006) The use of this protein to diagnose AKI has been most 
extensively studied in cardiac surgery. When evaluated in both adult and pediatric cardiac 
surgery patients, NGAL has shown good sensitivity and specificity for diagnosis of AKI, 
with a significantly earlier rise following injury when compared to creatinine. NGAL began 
to rise within two hours after renal insult, while creatinine rise occurred over a period of one 
to three days.(Mishra, Dent et al. 2005; Wagener, Jan et al. 2006; Dent, Ma et al. 2007; 
Bennett, Dent et al. 2008) NGAL levels have been shown predictive when measured both in 
the serum and the urine. The performance of NGAL in these and other clinical studies 
appears sufficient to recommend its inclusion in an early diagnostic panel for AKI, 
suggesting that we will likely see rapid expansion of its use in the coming years.  
4.5 Cystatin C 
Cystatin C is a cysteine protease inhibitor. Serum level of cystatin C is a reflection of GFR, 
making changes in serum and urine levels a reflection on changes in GFR. This is in 
contrast to NGAL, which is a reactive protein and a measure of tubular stress. Cystatin C 
levels are not significantly affected by age, race, gender, muscle mass, or infection, 
making it a better measure of GFR than serum creatinine.(Dharnidharka, Kwon et al. 
2002) Due to these promising characteristics, cystatin C has been investigated in a variety 
of clinical settings, including cardiac surgery. With the exception of one inconclusive 
study, cystatin C has consistently been shown superior to serum creatinine in predicting 
AKI following cardiac surgery.(Koyner, Bennett et al. 2008; Haase-Fielitz, Bellomo et al. 
2009; Heise, Waeschle et al. 2009) Cystatin C, like NGAL, also appears to offer prognostic 
value in this setting. When considering all available data, cystatin C appears to be a 
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reliable marker of chronic renal dysfunction and both cystatin C and NGAL are 
dependable early predictors of AKI. However, NGAL may slightly outperform in cystatin 
C as an early predictor of injury. 
4.6 Liver-type fatty acid binding protein (L-FABP) 
L-FABP is a protein expressed in various organs, including the kidney, and plays a role in 
the cellular uptake of fatty acids. The molecule is filtered and reabsorbed by the kidney, 
resulting in elevated urine L-FABP levels in the presence of decreased GFR.(Negishi, Noiri 
et al. 2008; Portilla, Dent et al. 2008; Negishi, Noiri et al. 2009) Some clinical studies have 
demonstrated usefulness for L-FABP in identifying patients at risk for AKI.(Nakamura, 
Sugaya et al. 2006) It has also shown promise as a marker for postoperative AKI, although it 
appears to rise later than NGAL.(Portilla, Dent et al. 2008) The literature to date suggests 
that L-FABP may be a useful addition to preoperative risk assessment and postoperative 
diagnosis of AKI, with further investigation being warranted. 
4.7 Interleukin-18 (IL-18) 
IL-18 is a proinflammatory cytokine and a reliable signal for ischemia-induced AKI in 
animal models.(Melnikov, Ecder et al. 2001) Data from pediatric cardiac surgery, kidney 
transplantation, and acute respiratory distress syndrome have shown that urine IL-18 
performs well as an early predictor of AKI.(Parikh, Abraham et al. 2005; Parikh, Jani et al. 
2006; Parikh, Mishra et al. 2006) A recent prospective observational trial questioned the 
specificity of IL-18 as a marker of renal injury in cardiac surgery, suggesting that it may be 
a non-specific sign of post cardiopulmonary bypass inflammation.(Haase, Bellomo et al. 
2008) As a consequence of these inconsistent results, IL-18 will require further 
investigation and validation before it can be considered for routine inclusion on urinary 
panels.  
4.8 Kidney injury molecule-1 (KIM-1) 
KIM-1 is a transmembrane glycoprotein that can be detected in the urine following 
AKI.(Zhang, Humphreys et al. 2007) Although it is not expressed in normal kidneys, KIM-1 
is upregulated following nephrotoxic or ischemic injury.(Han, Bailly et al. 2002) Clinical 
studies have suggested that KIM-1 may be useful in improving early detection of AKI 
following cardiac surgery, particularly when measured in conjunction with other novel 
biomarkers.(Han, Wagener et al. 2009) 
4.9 Summary of novel biomarkers of AKI in cardiac surgery 
The cause of AKI in cardiac surgery is multifactorial, making it is unlikely that a single 
biomarker will prove sufficiently accurate and reliable to be trusted for risk stratification 
and diagnosis of AKI. Outlined above are the most promising biomarkers, which recognize 
damage in different pathways of renal injury. Table 2 is a summary of novel biomarkers and 
their key properties. In the future, combinations of these markers, used in parallel with 
clinical parameters, will likely emerge as practical tools to help predict and verify the onset 
of AKI in a variety of settings, including cardiac surgery. 
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Biomarker Variable assessed Time to detection (h) 
Serum Cystatin GFR 12-14 
Serum NGAL Proximal tubular injury 2-4 
Urine NGAL Proximal tubular injury 2-4 
Urine L-FABP Proximal tubular injury 4-6 
Urine IL-18 Proximal tubular injury 4-6 
Urine KIM-1 Proximal tubular injury 12-24 
Table 2. Novel biomarkers for detection of acute kidney injury. GFR = glomerular filtration 
rate, NGAL = neutrophil gelatinase-associated lipocalin, L-FABP = Liver-type fatty acid 
binding protein IL = interleukin, KIM = kidney injury molecule. 
5. Risk factors for acute kidney injury 
5.1 Preoperative 
Prevention postoperative renal failure begins by identifying patients at risk. Several risk 
factors have been for postoperative AKI have been identified, some more consistently than 
others. One of the largest studies addressing the topic was published by Chertow et al in 
1997.(Chertow, Lazarus et al. 1997) This group developed a model for preoperative renal 
risk stratification by prospectively following 43,000 patients in 43 different centres over a 
seven-year period. The overall incidence of acute renal failure requiring dialysis was 1.1 %. 
Thirty-day mortality in patients requiring dialysis was 64%, compared to 4.3% for patients 
without renal failure. The authors identified ten clinical variables as independent predictors 
of dialysis dependant renal failure following cardiac surgery. (Table 3) These included 
preoperative renal dysfunction (OR 1.3-5.8, depending on creatinine clearance), valvular 
surgery (OR 1.98), intra-aortic balloon pump (OR 3.19), redo surgery (OR 1.93), NYHA class 
IV (OR 1.55), decreased left ventricular ejection fraction (OR 1.45), peripheral vascular 
disease (OR 1.51), chronic obstructive pulmonary disease (OR 1.26), pulmonary rales (OR 
1.37), and the extremes of systolic blood pressure. Based on these factors, the authors 
developed a clinical algorithm to quantify risk and identify patients most in danger of 
requiring postoperative dialysis. Mangano et al studied a smaller population and identified 
other preoperative characteristics associated with postoperative dialysis.(Mangano, 
Diamondstone et al. 1998) Similar to Chertow, they identified congestive heart failure (RR 
1.8), previous surgery (RR 1.8), and elevated creatinine (RR 2.3) as predisposing factors, and 
they also showed that age 70-79 years (RR 1.6) and 80-95 years (RR 3.5), type-1 diabetes (RR 
1.8), and elevated preoperative serum glucose (exceeding 16.6 mmol/L, RR 3.7) significantly 
increased the risk of postoperative dialysis. These findings have been echoed by several 
other studies.(Abrahamov, Tamariz et al. 2001; Diaz, Moitra et al. 2008) Preoperative renal 
dysfunction has consistently been the most predictive of postoperative renal complications. 
A preoperative creatinine between 175 and 350mmol/L is associated with a 10-20% risk of 
postoperative dialysis, while patients with a creatinine greater than 350mmol/L may have a 
25-28% risk of dialysis.(Frost, Pedersen et al. 1991; Chertow, Lazarus et al. 1997; Fortescue, 
Bates et al. 2000; Thakar, Liangos et al. 2003; Thakar, Liangos et al. 2003) Other authors have 
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also found female gender, left main coronary disease, concomitant liver disease, and pre-
existing sepsis to contribute to postoperative renal dysfunction.(Conlon, Stafford-Smith et 
al. 1999; Rosner and Okusa 2006; Rosner, Portilla et al. 2008) (Table 3) 
 
Preoperative renal dysfunction 
Valvular surgery 
Intra-aortic balloon pump 
Redo surgery 
NYHA class IV 
Decreased LVEF 
Peripheral vascular disease 
COPD  
Pulmonary rales 




Table 3. Risk factors for dialysis dependant renal failure following cardiac surgery. LVEF = 
Left ventricular ejection fraction, COPD = chronic obstructive pulmonary disease 
A significant modifiable risk factor that may play a role in postoperative AKI is the timing of 
surgery following contrast angiography. Medalion et al reviewed data on 365 patients who 
underwent CABG surgery.(Medalion, Cohen et al. 2010) Multivariate analysis identified 
several risk factors for postoperative AKI, including surgery within 24 hours of contrast 
administration and preoperative renal dysfunction (clearance < 60mL/min). Contrast dose 
greater than >1.4ml/kg was predictive of AKI if surgery was performed within five days of 
angiography. The authors suggest avoiding surgery within 24 hours of angiography 
whenever possible and delaying surgery for five days in patients having received a large 
contrast dose, particularly if the presence of chronic renal dysfunction.  
It is unclear whether medications such as nonsteroidal anti-inflammatory drugs and 
angiotensin receptor blocker should be discontinued prior to surgery. Several authors have 
suggested that these medications increase the risk of postoperative AKI.(Rosner, Portilla et 
al. 2008). Finally, genetic predispositions to AKI have been reported more recently. A study 
from Duke University found that patient with the inherited apolipoprotein epsilon-4 allele 
were less likely to develop AKI compared to patients with other forms of the allele.(Chew, 
Newman et al. 2000)  
It is essential to remember that preoperative renal dysfunction may not be obvious when 
looking at the creatinine alone. It is paramount to calculate the creatinine clearance for all 
patients, but particularly for those in extremes of age and body habitus, as this will permit a 
better identification of patients with increased risk of perioperative renal dysfunction. 
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5.2 Intraoperative risk factors 
Many preoperative risk factors have become accepted by the community, as a large amount 
of data suggested their role in the development of postoperative renal dysfunction. 
Intraoperative risk factors, however, are notoriously difficult to control for and are 
sometimes challenged. 
The maintenance of cardiovascular stability during CPB is dependant on many factors, 
including a proper functioning CPB circuit and patient factors, such as venous compliance, 
systemic vascular resistance, and autoregulatory systems. The goal of CPB is to maintain 
adequate end-organ perfusion at a level that allows optimal cellular functioning. Any 
deviation in perfusion pressure and flow rates can significantly affect the oxygen delivery to 
all organs and may result in periods of decreased flow or perfusion pressure, leading to 
renal injury.(Urzua, Troncoso et al. 1992; Fischer, Weissenberger et al. 2002)  
Prolonged cardiopulmonary bypass and aortic cross-clamp times are relatively well-
accepted as being linked to increased postoperative AKI, although this finding has not been 
present in all studies.(Fischer, Weissenberger et al. 2002; Tuttle, Worrall et al. 2003) 
Unfortunately, because of the heterogenous patient populations, no specific time frame has 
been established after which the risk of AKI increases. Additionally, although prolonged 
bypass times may play a role in postoperative AKI, it is likely a combination of all of the 
previously mentioned factors that will decide each individual patient’s propensity for 
postoperative renal dysfunction. Other modifiable characteristics of CPB that may influence 
the incidence of AKI include pulsatile versus non-pulsatile flow during CPB, and 
normothermic versus hypothermic CPB. However, neither of these factors has been shown 
clinically to affect the incidence of postoperative AKI.(Urzua, Troncoso et al. 1992; Abramov, 
Tamariz et al. 2003; Provenchère, Plantefève et al. 2003)  
Dilutional anemia during CPB has been associated with increased overall morbidity 
following cardiac surgery. Specifically, lowest on-pump hematocrit below 22-24% may put 
patients at risk for postoperative AKI.(Habib, Zacharias et al. 2003; Habib, Zacharias et al. 
2005) Aprotinin is a serine protease inhibitor that, until recently, was commonly given 
perioperatively to decrease blood loss related to open-heart surgery.(van Oeveren, Jansen et 
al. 1987; Royston 1995) It has been suggested that aprotinin may cause vasoconstriction of 
the afferent arteriole, thus reducing glomerular perfusion pressure and occasioning renal 
dysfunction. A propensity based analysis of over 4000 patients receiving aprotinin and other 
fibrinolytic agents perioperatively concluded that the administration of aprotinin was 
associated with a doubling of the risk acute renal failure requiring RRT.(Mangano, Tudor et 
al. 2006) This finding has since been supported and opposed by similar large observational 
studies.(Furnary, Wu et al. 2007; Dietrich, Busley et al. 2008; Shaw, Stafford-Smith et al. 
2008) More recently, an increased 30-day mortality in the aprotinin arm of the BART study 
(Blood Conservation Using Antifibrinolytics in a Randomized Trial) prompted the Food and 
Drug Administration to suspend marketing of the drug.(Fergusson, Hébert et al. 2008) 
5.2.1 On vs Off pump CABG 
One of the most debated topics on the subject of AKI prevention is the proposed renal 
protection offered by off-pump coronary artery bypass surgery (OPCAB) compared to 
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CABG with CPB. Advocates of off-pump surgery generally cite a reduced risk of AKI as a 
benefit of the OPCAB approach, however, there is little data to support this claim. Critics of 
OPCAB surgery suggest that instances of perioperative low cardiac output due to contortion 
of the heart may offset the detrimental effects of the CPB circuit. Niwekar et al. recently 
published a meta-analysis evaluating the results of on-pump vs off-pump surgery in 
twenty-two studies, including six randomized controlled trials (RCT) comprising over 
27,000 patients.(Nigwekar, Kandula et al. 2009) In the pooled analysis there was a reduction 
in the overall incidence of AKI and in AKI requiring RRT. In a separate analysis of the RCTs 
only, overall incidence of AKI was reduced but there was no significant difference in the 
proportion of patients requiring renal replacement therapy. It is worth noting that one of the 
major limitations of this report is the lack of a uniform definition of AKI across the studies. 
The authors also report that the RCTs tended to enroll healthier patients with a lower risk of 
postoperative AKI. This bias, combined with smaller sample sizes, made the RCTs 
underpowered to study AKI.  
In the absence of a randomized trial focusing on AKI after cardiac surgery, the best available 
evidence consists mostly of observational studies from which our conclusions must be 
drawn. Based on this data, it is reasonable to conclude that in patients at higher risk for AKI, 
an OPCAB approach, when appropriate, may reduce the likelihood of developing 
postoperative renal dysfunction. When interpreting this data, one must remember that renal 
protection is just one of the many important factors to consider when choosing an 
appropriate revascularisation method. The pros and cons of OPCAB versus CABG surgery 
with CPB must be analysed while considering each individual patient and each surgeon’s 
preference and experience.  
6. Prevention of postoperative AKI    
A vast number of therapies have been proposed for limiting the incidence of perioperative 
renal dysfunction. These range from simple manoeuvres, such as maintaining hydration, to 
more advanced pharmacological interventions. The most well studied methods will be 
reviewed here. 
6.1 Hydration 
There is little argument that adequate hydration is a prerequisite to maintaining healthy 
kidney function.  A randomized study evaluating contrast-induced nephropathy compared 
patients receiving an intravenous infusion of sodium chloride for twelve hours preceding 
their intervention to a control group of patients with unrestricted fluid ingestion. The 
authors found that intravenous fluid administration protected patients from AKI.(Trivedi, 
Moore et al. 2003) Other studies have echoed these results, particularly in patients with 
underlying renal dysfunction.(Solomon, Werner et al. 1994; Dussol, Morange et al. 2006) 
Another randomized trial compared a regimen of half-isotonic saline infusion to standard 
preoperative fluid restriction in patients with known renal dysfunction, defined as 
glomerular filtration rate <45mL/min.(Marathias, Vassili et al. 2006) Patients in the 
hydration group were significantly less likely to develop postoperative renal failure and no 
patients required RRT, compared to 27% of patients in the control group. While these may 
be arguments for preoperative fluid loading and avoiding perioperative hypovolemia, the 
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ideal method of perioperative volume resuscitation remains a highly debated topic. Much 
effort has been put into identifying the ideal fluid, or ideal combination of fluids, to 
maintain perioperative circulating volume. This question has been investigated most 
thoroughly in the critical care literature, with several observational studies, randomized 
trials, and meta-analyses addressing the issue. Unfortunately, many studies have had 
conflicting results and little has been concluded on the subject.(Choi, Yip et al. 1999; Finfer, 
Bellomo et al. 2004; Roberts, Alderson et al. 2004; Rioux, Lessard et al. 2009; Bunn, Trivedi 
et al. 2011) Regarding renal failure specifically, a recent Cochrane review found that 
evidence was lacking to conclude that colloid use is associated with renal failure in a non-
septic population.(Dart, Mutter et al. 2010) Data specific to cardiac surgery is also 
available but offers little help. A recent randomized pilot study by Magder et al compared 
the use of colloids to crystalloids in a postoperative cardiac surgery population.(Magder, 
Potter et al. 2010) The colloid based resuscitation protocol was associated with less 
catecholamine use, a lower incidence of pneumonia and mediastinal infection, and less 
need for cardiac pacing. A conflicting study found that there was indeed a dose-
dependant relationship between pentastarch administration and AKI, with an optimal 
cutoff volume at 14mL/kg.(Rioux, Lessard et al. 2009) It is likely that either colloids or 
crystalloids are suitable solutions for fluid resuscitation and that a balanced resuscitation 
avoiding high doses of colloids or crystalloids alone would lead to optimal patient 
outcome. 
6.2 Glycemic control 
In 2001, van den Berghe published a seminal randomized trial establishing the benefit of 
intensive insulin therapy to maintain tight glycemic control in postoperative critically ill 
patients.(van den Berghe, Wouters et al. 2001) More than 60% of patients studied had 
undergone cardiac surgery. In addition to a significant mortality benefit, intensive insulin 
therapy was associated with a 41% reduction in patients requiring dialysis or hemofiltration. 
A subsequent large observational study found an even more prominent effect on prevention 
of AKI after instituting a similar protocol. (Krinsley 2004) Studies addressing diabetic 
patients specifically have also found increased postoperative AKI associated with poor 
perioperative glycemic control, however, it is unclear whether interventions to treat and 
prevent hyperglycemia can improve outcomes in this population.(Furnary, Gao et al. 2003; 
Ouattara, Lecomte et al. 2005) In fact, some groups have found that although tight glycemic 
control can prevent AKI, there may be a tradeoff for other complications, such as an 
increased incidence of death and stroke.(Gandhi, Nuttall et al. 2007; Investigators, Finfer et 
al. 2009) 
6.3 Dopamine 
Dopamine is an endogenous catecholamine with dose-dependent effects on dopaminergic, 
alpha- and beta1-adrenergic receptors. Experimentally, dopamine stimulates the renal 
dopaminergic receptors to result in increased renal blood flow and GFR, and acts as a 
diuretic and natriuretic. Based on promising studies in animals and healthy volunteers, the 
clinical use of low-dose dopamine (3 mg/kg/min) became popular and has been used 
routinely in some institutions.(MacGregor, Smith et al. 2000) Unfortunately, these results 
have not been reproduced in clinical reports, including several well-designed studies and 
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meta-analyses.(Kellum 1997; Marik and Iglesias 1999; Bellomo, Chapman et al. 2000; Marik 
2002) After reviewing the available data from 1966-2000, comprised of 2149 patients, Kellum 
at el concluded that “the use of low-dose dopamine for the treatment or prevention of acute 
renal failure cannot be justified on the basis of available evidence and should be eliminated 
from routine clinical use.”(Kellum and M  Decker 2001)  
6.4 Other dopaminergic drugs 
Fenoldopam is a synthetic derivative of dopamine with DA1 receptor selectivity that 
increases blood flow to the kidneys.(Mathur, Swan et al. 1999; Meco and Cirri 2010) Several 
small studies have reported favorable effects of fenoldopam on GFR and serum creatinine in 
cardiac surgery patients.(Halpenny, Lakshmi et al. 2001; Caimmi, Pagani et al. 2003; 
Garwood, Swamidoss et al. 2003) However, a number of well-designed trials have found no 
benefit with fenoldopam when compared to placebo, dopamine, or other treatments.(Bove, 
Landoni et al. 2005; Morelli, Ricci et al. 2005; Brienza, Malcangi et al. 2006) A 2007 meta-
analysis published pooled results from 16 RCTs and concluded that fenoldopam reduces the 
need for renal replacement therapy and mortality in patients with AKI.(Landoni, Biondi-
Zoccai et al. 2007) The results of this analysis may be questioned, however, due to the 
heterogeneity of the trials, including an inconsistant definition of AKI and no clear criteria 
for the commencement of renal replacement therapy. Dopexamine is a predominantly B2-
agonist. This molecule has been less-thoroughly studied than the other dopamingeic drugs, 
but existing data is also inconsistent.(Hakim, Foulds et al. 1988; Stephan, Sonntag et al. 1990; 
MacGregor, Butterworth et al. 1994; Sherry, Tooley et al. 1997) As a result, dopexamine 
cannot be recommended as an effective way to reduce postoperative AKI. 
Although none of the dopaminergic medications appear to be associated with prohibitive 
side effects, the evidence to date does not support their use in the context of preventing AKI 
following cardiac surgery. Further study may be warranted in the case of fenoldopam. 
6.5 Loop diuretics 
Furosemide is a loop diuretic that inhibits sodium absorption in the medullary portion of 
the loop of Henle. It has been suggested that by decreasing tubular cell workload, it may 
limit hypoxia within the nephron. Although this theoretical mechanism exists, there is little 
evidence supporting its use in preventing and treating AKI. Ho et al performed a meta-
analysis of nine randomized controlled trials studying 849 patients with an increased risk of 
renal failure.(Ho and Sheridan 2006) A pooled analysis of the data failed to show 
improvements in mortality, requirement of RRT, or number of dialysis sessions. The review 
also found that high doses of furosemide put patients at risk for deafness and tinnitus. An 
earlier systematic review reported similar results. Not only has administration of loop 
diuretics failed to show a benefit when given in the perioperative setting, there is evidence 
that if may worsen renal dysfunction. Lassnigg et al randomized 126 low-risk patients to 
receive furosemide infusion, low-dose dopamine, or saline infusion during and after 
cardiac surgery.(Lassnigg, Donner et al. 2000) The maximum postoperative creatinine was 
doubled in the furosemide group compared to the other two groups. The mechanism of 
increased renal injury was not clearly elucidated but intravascular hypovolemia likely 
played a role. 
www.intechopen.com
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
141 
In summary, there is no clear evidence to support the use of loop diuretics in decreasing the 
incidence or extent of renal injury following cardiac surgery. These medications should be 
prescribed when indicated for volume overload and other clinically appropriate scenarios.  
6.6 Mannitol 
Mannitol is an osmotic diuretic with several suggested benefits in the perioperative period. 
Theoretically, it increases intravascular volume, improving preload and cardiac output, 
increases blood to the kidneys through the release of atrial natriuretic peptide, and facilitates 
the flushing of debris from renal tubules by increasing urinary output.(Better, Rubinstein et 
al. 1997) Mannitol is known to have additional properties as a free radical scavenger, which 
may help attenuate the effects of reperfusion injury. Routine mannitol use became popular 
in cardiac surgery as a result of limited data published several decades ago.(BARRY and 
BERMAN 1961) More recent publications have consistently failed to show a benefit with 
mannitol therapy when given in the perioperative period.(Ip-Yam, Murphy et al. 1994; 
Better, Rubinstein et al. 1997; Poullis 1999; Carcoana, Mathew et al. 2003) 
In light of these results, although it has become routine practice in many institutions to add 
mannitol to the pump prime solution, there is little evidence to support this therapy. It is 
also important to consider the possible detrimental effect of induced osmotic diuresis, which 
may include hypovolemia and hypernatremia. Unfortunately, until more robust data is 
available, individual cardiac surgery teams must base their decision to use mannitol on their 
own interpretation of the limited information available in the literature. 
6.7 N-acetylcysteine 
There is conflicting evidence supporting the use of the antioxidant n-acetylcysteine in the 
prevention of contrast-induced nephropathy.(Marenzi, Assanelli et al. 2006; Krämer and 
Hoffmann 2007) When studied in high-risk patients undergoing on-pump cardiac surgery, 
n-acetylcysteine failed to show a benefit compared to placebo in the prevention of 
postoperative renal failure.(Burns, Chu et al. 2005; El-Hamamsy, Stevens et al. 2007; Haase, 
Haase-Fielitz et al. 2007; Sisillo, Ceriani et al. 2008) Several meta-analyses reviewing this 
subject support the results of these individual trials.(Baker, Anglade et al. 2009; Nigwekar 
and Kandula 2009) The lack of benefit in cardiac surgery populations compared to contrast-
induced nephropathy is likely related to the different mechanism of AKI, which is more 
clearly related to ischemia-reperfusion injury than nephrotoxicity.  
6.8 Calcium channel blockers 
Calcium channel blockers have been shown experimentally to promote renal vasodilatation, 
increase renal blood flow, and increase GFR. Studies in patients undergoing cardiac surgery 
have been contradictory.(Young, Diab et al. 1998; Piper, Kumle et al. 2003)  
6.9 Natriuretic peptides 
Natriuretic peptides are known to oppose the renin-angiotensin-aldosterone and arginine 
vasopressin systems through multiple mechanisms.(Nakao, Itoh et al. 1989) As a result they 
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can induce natriuresis and vasodilatation to prevent hypervolemia and oppose the 
vasoconstrictive response induced by hypovolemia. Synthetic analogues of these proteins 
have been suggested as therapies to prevent renal failure following cardiac surgery.  
Anaritide, the human recombinant form of atrial natriuretic peptide (ANP), is 
administered intravenously to induce arterial and venous dilatation, thus decreasing 
blood pressure. This drug failed to show a benefit in two randomized controlled trials of 
critically ill patients with acute tubular necrosis.(Allgren, Marbury et al. 1997; Lewis, 
Salem et al. 2000) 
Nesiritide, a human recombinant form of Brain-type natriuretic peptide (BNP) is used in 
the treatment of decompensated heart failure. In a randomized controlled trial of heart 
failure patients, nesiritide improved diuresis and decreased pulmonary congestion and 
edema.(Mills, LeJemtel et al. 1999) Despite these benefits, a recent meta-analysis raised 
concerns about a possible detrimental effect on renal function.(Sackner-Bernstein, 
Skopicki et al. 2005) More recently, the NAPA investigators randomized 303 patients with 
left ventricular dysfunction undergoing cardiac surgery to receive nesiritide or 
placebo.(Mentzer, Oz et al. 2007) The primary outcomes were postoperative renal 
function, hemodynamics, and drug use.  The authors found that nesiritide attenuated 
peak increase in creatinine, decreased hospital stay, and improved survival at 180 days. 
Two other randomized trials published in recent years showed favorable laboratory 
results in the nesiritide groups, however, they failed to show a significant clinical 
benefit.(Chen, Sundt et al. 2007; Ejaz, Martin et al. 2009) Although data regarding this 
drug has been conflicting, interesting results would suggest that further investigation is 
justified.  
6.10 Sodium bicarbonate 
Sodium bicarbonate is known to alkalinize urine and, when given intravenously, has been 
shown to attenuate renal dysfunction in the context of contrast infusion.(Merten, Burgess et 
al. 2004; Briguori, Airoldi et al. 2007; Recio-Mayoral, Chaparro et al. 2007) A recent 
randomized pilot study evaluated the effect of perioperative sodium bicarbonate infusion in 
a group of patients at increased risk of renal failure undergoing cardiac surgery.(Haase, 
Haase-Fielitz et al. 2009) Patients were randomized to receive a 24-hour infusion of sodium 
bicarbonate or sodium chloride, beginning just after the induction of anesthesia. A lower 
rate of renal dysfunction was found in the treatment group, evidenced by a lower incidence 
of increased creatinine and neutrophil gelatinase-associated lipocalin. Base on these results, 
the authors suggest that further trials are merited  
6.11 Summary of results for preventive strategies 
It is not surprising that no single molecule has been shown unequivocally to prevent or 
effectively treat renal failure following cardiac surgery. The mechanisms of renal injury are 
multifactorial and the incidence of significant renal failure requiring is RRT is relatively low. 
Additionally, most RCTs enroll low risk patients, making most studies underpowered to 
demonstrate any benefits that may exist. The two drugs that have shown the most promise 
and would benefit from further study are fenoldopam and nesiritide. 
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7. Principles of treatment and renal replacement therapy 
7.1 General principles and supportive care 
Once the diagnosis of AKI has been established, it is important to understand the clinical 
situation and initiate supportive care without delay. As with any patient in an acute care 
setting, vital signs and basic hemodynamics must be evaluated. Assessment of cardiac 
output and filling pressures will give clues as to whether cardiac tamponade should be 
suspected. Subsequently, any drugs with potentially adverse effects on the kidney should be 
identified and, if possible, withdrawn. Finally, it is important to complete the clinical 
picture, with the help of additional laboratory tests if necessary, and determine whether 
there is a renal or pre-renal cause of injury. 
Serum values of BUN, creatinine, electrolytes and osmolality, as well as examination of 
urinary sediment, electrolytes and osmolality, will help determine whether there is a pre-
renal cause correctable with fluid administration, or if an acute tubular injury is more likely. 
For example, a slight increase in creatinine with a large jump in BUN often suggests a pre-
renal process, while a proportional rise in BUN and creatinine often signals AKI. Urine 
sodium >20 mEq/L and urine osmolality >500mOsm/kg are often seen in pre-renal 
disease. Calculation of the fractional excretion of sodium (FENa) can be useful in oliguric 
patients, with FENa <1% reflecting preserved renal function, consistent with a pre-renal 
disease state. FENa will usually be >2% in the context of AKI with impaired kidney 
function.  (See Table 1) 
Once the nature of kidney injury is understood, the practical management of patients with 
acute renal failure remains primarily supportive. If pre-renal oliguria is likely, it should be 
treated early and aggressively to prevent further tubular injury and loss of renal function. If 
AKI is established, only supportive care can be offered and efforts must be directed toward 
prevention of further kidney damage, hypervolemia, and treatment of metabolic and 
electrolyte issues as they arise. Frequent assessment of electrolytes, blood glucose, and acid-
base balance is imperative to permit corrections if necessary.  
When AKI is suspected or proven, optimization of hemodynamics should be prioritized to 
prevent further injury. Practically speaking, this includes optimizing preload and cardiac 
output. If oliguria persists despite these measures, symptomatic treatment can be instituted. 
This included managing the consequences of renal failure, which include hypervolemia, 
hyperkalemia, acidosis, and hyperphosphatemia.  
As a result of earlier diagnosis and greater access to dialysis, mortality from hyperkalemia 
has decreased significantly. In patients with AKI, it is important to restrict daily potassium 
intake by withholding food and medications containing potassium. When potassium levels 
become high or ECG changes develop, emergency treatment may include intravenous 
infusion of calcium, sodium bicarbonate, or glucose and insulin, or an inhaled beta-
agonist(Kim and Han 2002). These medications cause an intracellular potassium shift, thus 
decreasing serum levels. Since these medications do not actually remove potassium from the 
body, their effect is only temporary, and other interventions are necessary to eliminate it 
from the body. Administration of loop diuretics can be useful to eliminate potassium, 
however, varied responses to this medication render the effect unreliable. A sodium-
potassium exchange resin, such as sodium polystyrene sulfonate (Kayexalate), can be 
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effective in removing potassium, although the maximal effect occurs only after 4-6 hours. 
Kayexalate can be administered orally or intrarectally in doses of 15-60 grams, one to four 
times daily. The most significant complication of Kayexalate administration is 
gastrointestinal necrosis, which occurs very rarely but can be extremely morbid. 
Constipation is a more common side effect. While loop diuretics and Kayexalate are options 
in select patients, the most effective and rapid method of potassium elimination is 
hemodialysis.  
Acidosis occurs frequently in acute renal failure, often complicating treatment in the 
critically ill patient due to altered homeostasis, decreased cardiac contractility, and 
attenuated responses to catecholamines. Management of metabolic acidosis should focus on 
correction of the cause and concomitant morbidity. If acidosis remains once treatment is 
optimized, hemodialysis is the most effective and proven method of correction. There is 
significant controversy regarding the use of bicarbonate in management of acidosis in the 
critically ill patient. Observational and randomized studies have failed to show a mortality 
or morbidity benefit when sodium bicarbonate is administered to correct acidosis.(Forsythe 
and Schmidt 2000; Kraut and Kurtz 2001; Kurtz, Kraut et al. 2008) The proposed rationale 
for the lack of benefit is that, while bicarbonate may increase extracellular pH, it exacerbates 
intracellular acidosis by the generation of carbon dioxide in the buffering process. 
Consequently, the practice of many critical care physicians is to administer sodium 
bicarbonate only in the presence of profound acidosis (pH <7.1) and associated 
hemodynamic instability. The goal of treatment should be a pH of approximately 7.2. 
Continuous infusion is favored over bolus injection in order to limit carbon dioxide 
production.(Kraut and Madias 2010) 
As discussed above, loop diuretics have not been shown to prevent or attenuate renal 
failure. Despite a seemingly positive effect on urine output, the available literature suggests 
that routine furosemide administration may even have deleterious effects, particularly if 
given at high doses or if it results in an unwarranted delay in commencement of 
RRT.(Kellum, Leblanc et al. 2008) Furosemide may be useful when acute kidney injury is 
accompanied by hyperkalemia or hypervolemia. If none are present, furosemide is not 
indicated.  
7.2 Renal replacement therapy 
7.2.1 Indications 
The primary roles of the kidney are to excrete toxins, maintain volemia, control electrolytes, 
and preserve acid-base homeostasis. Failure of the kidneys to perform any of these functions 
may precipitate an urgent indication for RRT. While there are no absolute guidelines 
mandating the initiation of RRT in the context of acute kidney injury, generally accepted 
indications for RRT in critically ill patients include electrolyte imbalances, hypervolemia 
with pulmonary edema, uremia, and metabolic acidosis. Specific suggested criteria are 
described in Table 4.  
There is an ongoing debate regarding the ideal timing of initiation of RRT in the critically-ill 
patient, particularly following cardiac surgery. Several factors are responsible for the lack of 
a definitive answer, including the heterogeneous definition of AKI in the literature and a 
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paucity of well-designed studies. Bouman et al analysed two RCTs and four retrospective 
studies addressing the question.(Bouman and Oudemans-Van Straaten 2007) Five of these 
studies, two of which focused uniquely on cardiac surgical patients, found a survival 
advantage with earlier initiation of RRT.(Gettings, Reynolds et al. 1999; Bouman, 
Oudemans-Van Straaten et al. 2002; Demirkiliç, Kuralay et al. 2004; Elahi, Lim et al. 2004; 
Jiang, Xue et al. 2005; Piccinni, Dan et al. 2006) Unfortunately the criteria for early and late 
initiation were different for each study and, due to the retrospective nature of several 
studies, they were fraught with confounding variables. In general, criteria for early initiation 
was dependent on oliguria, while late RRT was instituted based on serum biomarkers or 
clinical indications. The single randomized study in a surgical population found no 
difference in mortality between the early and late initiation groups.(Bouman, Oudemans-
Van Straaten et al. 2002) However, it has been suggested that the severity of disease in this 
study was too low to demonstrate a significant difference between the two approaches, 
resulting in an underpowered trial.(John and Eckardt 2007) Conversely, there may have 
been a significant selection bias in the retrospective studies showing a benefit with early 
RRT. The question of early versus late initiation of RRT will remain until larger RCTs are 
available. In the interim, it may be reasonable to consider early hemodialysis in patients 
with other organ failure, persistent shock, or to avoid the contribution of acidosis and 
electrolyte abnormalities to an underlying shock state.  
 
Indication Description 
Metabolic acidosis • pH < 7.0 
Electrolyte 
abnormalities 
• Hyperkalemia (>6.5mmol/L) 
• Hyper/hyponatremia (Na >155 or <120 mmol/L)  
Fluid overload • Pulmonary edema 
• Oliguria (urine output <200mL/12 hours) 
• Anuria (urine output <50mL/12 hours) 
Uremia • Azotemia (Urea >30mmol/L) 
• Neuropathy, myopathy 
• Encephalopathy 
• Pericarditis 
Table 4. Proposed indications for RRT in acute renal failure. Adapted from John et al, 2007 
(John and Eckardt 2007) 
7.2.2 Dosing and mode of RRT 
A detailed discussion of the many dosing regimens and modes of RRT is beyond the scope 
of this chapter. Numerous retrospective and randomized trials have studied each of these 
topics, with a brief summary of the literature presented here.  
The quantification of urea removal is usually referred to as the dose of dialysis. It is an 
important parameter when measuring the efficiency of RRT, with increased removal of urea 
being equivalent to a higher dialysis dose. While there is some evidence suggesting that a 
www.intechopen.com
 
Renal Failure – The Facts 
 
146 
very low dialysis dose (0.5-0.6L/hr) is associated with worse outcomes, the results of several 
studies with regard to moderate  (20mL/kg/hr) or high dosing (35mL/kg/hr) have been 
either neutral or in favour of high doses.(Storck, Hartl et al. 1991; Ronco, Bellomo et al. 2000; 
Bouman, Oudemans-Van Straaten et al. 2002) The VA/NIH Acute Renal Failure Trial 
Network study randomized 1124 patients undergoing either intermittent hemodialysis 
(hemodynamically stable) or continuous venovenous hemodiafiltration (hemodynamically 
unstable) to low intensity or high intensity regimens.(Network, Palevsky et al. 2008) At 60 
days, there was no difference between the two groups in the rate of mortality, recovery of 
kidney function, or the rate of nonrenal organ failure. The authors suggest that other 
strategies will be necessary to decrease mortality in critically ill patients with acute kidney 
injury.  
 
 Intermittent hemodialysis Continuous renal replacement 
therapy 
Advantages • Lower risk of systemic bleeding 
• More time available for 
diagnostic and therapeutic 
interventions 
• More suitable for severe 
hyperkalemia 
•  Lower cost 
• Better hemodynamic stability 
• Fewer cardiac arrhythmias  
• Improved nutritional support  
• Better pulmonary gas exchange  
• Better fluid control 
• Better biochemical control Shorter 
stay in intensive-care unit 
Disadvantages • Availability of dialysis staff 
• More difficult hemodynamic 
control  
• Inadequate dialysis dose 
• Inadequate fluid control  
• Inadequate nutritional support 
• Not suitable for patients with 
intracranial hypertension 
• No removal of cytokines  
• Potential complement activation 
by non-biocompatible 
membranes 
• Greater vascular access problems  
• Higher risk of systemic bleeding  
• Long-term immobilization of 
patient  
• More filter problems (ruptures, 
clotting)  
• Greater cost 
Table 5. Advantages and disadvantages of intermittent versus continuous renal replacement 
therapy. Adapted from Lemaire et at, 2009(Lemaire, Jones et al. 2009) 
The mode of RRT is a complex subject, primarily because such a wide variety of modes 
exist. The two principle categories of RRT are intermittent hemodialysis (IHD) and 
continuous renal replacement therapy (CRRT). Intermittent hemodialysis is performed over 
several hours at variable intervals, ranging from once daily to three times per week. 
Sustained, low-efficiency dialysis (SLED) and extended daily dialysis are subgroups of IHD 
and are useful in less stable patients that may not tolerate large fluid shifts.(Kihara, Ikeda et 
al. 1994) CRRT, which is performed continuously, uses much slower flow rates compared to 
IHD, thus affording better hemodynamic stability. The most common modes of CRRT are 
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continuous venovenous hemofiltration, continuous venovenous hemodialysis, and 
continuous venovenous hemodiafiltration(Pannu, Klarenbach et al. 2008) One of the 
significant disadvantages  of CRRT is the requirement for anticoagulation due to the slower 
flow through the system. In the postoperative setting with a patient at increased risk of 
bleeding, alternative strategies can be applied, such as regular saline flushes or citrate 
infusion.(Kutsogiannis, Gibney et al. 2005)  
Pannu et al reviewed data from 9 RCTs and found no difference in survival between IHD 
and CRRT.(Pannu, Klarenbach et al. 2008) Despite these equivocal results, there may be 
distinct clinical advantages for individual patients that must be considered. For example, 
while IHD might be an obvious choice for patients who have passed the critical stage of 
their illness, a patient in severe shock on high doses of catecholamines would be more likely 
to tolerate CRRT. Cost is another important consideration, with IHD being considerably less 
costly. Table 5 summarizes the advantages and disadvantages of IHD and CRRT in the ICU 
setting. 
8. Summary 
Acute kidney injury is one of the most common complications following cardiac surgery, 
particularly in high-risk patients. Although our understanding of the pathophysiology of 
AKI has improved over time, we have been unable to significantly improve the prognosis of 
patients with this serious complication. Strategies for prevention, diagnosis and treatment 
are still in development, with significant effort being put into advancing our knowledge and 
progressing beyond our current limitations. While it is clear that further study is necessary 
to address the shortcomings in the variety of topics reviewed here, there is no substitute for 
astute clinical evaluation and adherence to basic principles of care in critically ill patients. 
Clinicians must be conscious of individual patient’s risks and recognize early signs of AKI in 
order to optimize treatment and limit sequelae.  
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